Clinical Trials
28 trialspanSOHO
Bayer
ANTARES
Instituto do Cancer do Estado de São Paulo
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
KEYVIBE-005
Merck Sharp & Dohme LLC
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Universidade Federal de Pernambuco
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
ASPIRE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Duke University
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Metastatic Cancer
Duke University
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
NYU Langone Health
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center